Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases.
The Next Generation Antibody Therapeutics market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market.
However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for Next-Generation Antibody Therapeutics Market.
Based on technology, the Next Generation Antibody Therapeutics market is segmented into Bispecific Antibodies (BsAbs), Biosimilar Antibody (Ab) Products, Antibody-Drug Conjugates (ADCs), Fc-engineered Antibodies, Antibody Fragments and Antibody-Like Proteins (AF & ALPs), and others. Among these, ADCs accounted for the largest market share in 2018 and estimated to dominate during the forecast period. The advancement in ADC technology is one of the major trends in the next-generation antibody therapeutics market. The ADC technology combines cytotoxic potential of chemotherapy and advantageous characteristics of antibodies, which leads to high specificity and efficiency of ADCs. The ADC technology is majorly used for the manufacturing of next-generation antibody therapeutics for treating cancer. The ADCs are manufactured by linking an anti-cancer drug, or another therapeutic agent to an antibody or antibody fragment. Because of high efficiency delivered by ADCs, various pharmaceutical companies, such as Seattle Genetics Inc., ImmunoGen Inc.,
Geographically, the market is divided into North America, Europe, South America, Asia-Pacific and the Middle East and Africa.
North America holds the dominant market share for next generation antibody therapeutics in 2018, and it is expected to maintain the growth over the forecast period, owing to the increasing research & development activities, technological advancement in antibody therapies, rising healthcare expenditure and increasing government initiatives in this region. In addition, rising incidence of chronic diseases, and increasing approvals for new drugs are also driving the growth of the market.
Asia-Pacific next generation antibody therapeutics market is growing at the highest CAGR during the forecast period (2019-2026), due to rising demand from the developing countries such as India and China.
Some of the major players in the Next Generation Antibody Therapeutics market are: Bayer AG, Amgen Inc., AstraZeneca PLC., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Biogen, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, ImmunoGen Inc., Seattle Genetics Inc., among others.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
